PL BioScience announces new Board Member PL BioScience announces Ole Henrik Bang-Andreasen as the newest Member of the Board PL BioScience has revealed that Ole Henrik Bang-Andreasen has been appointed to its Board of Directors, following the passing of board member Reinhard Vogt. Ole brings significant experience and
PL BioScience Reveals Fall 2025 Conferences Attendance PL BioScience announces participation in upcoming conferences this fall PL BioScience has revealed its participation in six upcoming Fall 2025 conferences. As part of its global strategy, the company will be represented in the following conferences in Asia and Europe:
PL BioScience Announces Major Site Expansion in September 2025 Key Milestone for PL BioScience as new headquarters are announced PL BioScience announced the next major step in its expansion – an upcoming move to a new 1,200 m² facility in Aachen, in September 2025. This key milestone
PL BioScience announces Strengthening of Management Team Appointment of Oliver Dick as new Chief Technology Officer PL BioScience announced the strengthening of its management team with the appointment of Oliver Dick, PhD. Oliver Dick joins the team as Chief Technology Officer, a strategic position as the company
First Artificial Human Platelet Lysate PL BioScience Raises the Bar in Cell Culture Technology with artificial HPL PL BioScience develops worldwide first artificial Human Platelet Lysate (HPL) solution, and thus a key ingredient for the research & production of cell-based pharmaceuticals. In partnership with the Korean biotech
We are thrilled to unveil our latest innovation: ELAREM™ Ultimate-FD PLUS The gamma irradiated Human Platelet Lysate ELAREM™ Ultimate-FD PLUS is designed to meet the needs of cell manufacturing applications requiring proven viral reduction. As a xeno-free cell culture supplement, ELAREM™ Ultimate-FD PLUS supports the safe and
We are thrilled to be able to offer the Stem Cell Network NRW the chance to visit our company in Aachen on 16 March 2022. Most of our employees at PL BioScience are scientists or have a scientific background. Therefore, we comprehend very well how difficult it
PL BioScience starts up complementary workspace at Medace The Aachen-based biotechnology company PL BioScience was founded in 2015 as a spin-off of the RWTH Aachen University, with the idea of delivering animal component-free cell culture supplements. PL BioScience has developed an advanced nutrient solution for
PL BioScience raises € 3.7 mln from Born2Grow, Brightlands Venture Partners, TechVision Fund I and more The capital will be used to expand R&D, increase sales capacity and scale up in-house production PL BioScience produces a human-based nutrient medium for growing cells, as replacement for animal-derived
ELAREM™ Prime is the worldwide first affordable cell culture supplement based on human platelets offering the same benefits as FBS – in an animal serum-free environment. What is ELAREM™ Prime? It is derived from reused transfusion-approved platelets. These platelets can no longer be used for blood transfusions,
Introducing our new human Platelet Lysate brand name: ELAREM™ As a university spin-off, we started manufacturing our human Platelet Lysates (hPL) back in 2015, as ‘PL Solution’ products. For more than five years, you may know our human Platelet Lysates under this name. It is time
It is a pleasure for us to announce that BORN2GROW GmbH & Co. KG, a subsidiary of Zukunftsfonds Heilbronn (ZFHN), invests in our company and technology. Since almost 20 years the ZFHN successfully consults and accompanies start-up technologies and companies. BORN2GROW is the second investor in
The TechVision Fonds brings in new capital in PL BioScience We are proud to announce that with the support of SilverSky LifeSciences we successfully managed to convince the TechVision Fonds to invest in our start-up business. The TechVision Fonds, managed by the S-UBG group, supports innovative start-up
